This study aimed to assess the metabolic effects, changes in daily life, and diabetes burden associated with automated insulin delivery (AID) systems in children in a real-world setting after 2 years of use. Longitudinal glycaemic data (glycated haemoglobin HbA1c, time in range TiR, time below range TbR, glucose management indicator GMI), body mass index (BMI), and AID system usage were collected from 111 children with type 1 diabetes at 12 and 24 months of AID use. After 1 year, adolescents and parents completed questionnaires on diabetes-related distress (P-PAID-C, P-PAID-T, and PAID-T) and experienced changes. Regardless of age or previous therapy, the HbA1c level decreased from 8.1 % (65 mmol/mol) to 7.7 % (61 mmol/mol), TiR increased from 55 % to 64 %, TbR decreased from 2.6 % to 1.8 %, and GMI (7.6 % vs. 7.3 %) improved after 1 year. After 2 years, HbA1c (7.6 % 60 mmol/mol), TiR (62 %), TbR (1.3 %), and GMI (7.4 %) levels stabilised. Adolescents and parents reported improvements in daily life (i.e. sleep, stress, fear of hypoglycaemia). However, the BMI-SDS scores increased in the first year. AID system use is associated with clinically relevant improvements in glycaemic control and decrease in daily diabetes-related burden on affected children and their parents.
Hoppmann et al. (2025) studied this question.